Summary
Peripheral T-cell lymphoma (PTCL) is a very aggressive and heterogeneous hematological malignancy and has no effective targeted therapy. The molecular pathogenesis of PTCL remains unknown. In this study, we chose the gene expression profile of GSE6338 from the Gene Expression Omnibus (GEO) database to identify hub genes and key pathways and explore possible molecular pathogenesis of PTCL by bioinformatic analysis. Differentially expressed genes (DEGs) between PTCL and normal T cells were selected using GEO2R tool. Gene ontology (GO) analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway analysis were performed using Database for Annotation, Visualization and Integrated Discovery (DAVID). Moreover, the Search Tool for the Retrieval of Interacting Genes (STRING) and Molecular Complex Detection (MCODE) were utilized to construct protein-protein interaction (PPI) network and perform module analysis of these DEGs. A total of 518 DEGs were identified, including 413 down-regulated and 105 up-regulated genes. The down-regulated genes were enriched in osteoclast differentiation, Chagas disease and mitogen-activated protein kinase (MAPK) signaling pathway. The up-regulated genes were mainly associated with extracellular matrix (ECM)-receptor interaction, focal adhesion and pertussis. Four important modules were detected from the PPI network by using MCODE software. Fifteen hub genes with a high degree of connectivity were selected. Our study identified DEGs, hub genes and pathways associated with PTCL by bioinformatic analysis. Results provide a basis for further study on the pathogenesis of PTCL.
Similar content being viewed by others
References
Leval LD, Bisig B, Thielen C, et al. Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol, 2009,72(2):125–143
Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood, 2011,117(25):6756–6767
Armitage James O.. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol, 2012,87:511–519
Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol, 2014,170(6):1226–1236
Martin-Sanchez E, Odqvist L, Rodriguez-Pinilla SM, et al. PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. Plos One, 2014,9(9):e112148
Pearson Joel D, Lee Jason KH, Bacani Julinor TC, et al. NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. J Signal Transduct, 2012,2012(4):123253
Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol, 2011,47(1):11–23
O’Leary H, Savage KJ. The spectrum of peripheral T-cell lymphomas. Curr Opin Hematol, 2009,16(4):292
Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med, 2011,364(8):775–776
Intlekofer AM, Younes A. From empiric to mechanism-based therapy for peripheral T cell lymphoma. Int J Hematol, 2014,99(3):249–262
Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with singleagent brentuximab vedotin. Blood, 2014,123(20):3095–3100
Dunleavy K, Piekarz RL, Zain J, et al. New Strategies in Peripheral T-cell lymphoma: Understanding Tumor Biology and Developing Novel Therapies. Clin Cancer Res, 2010,16(23):5608
Moskowitz AJ, Lunning MA, Horwitz SM. How I treat the peripheral T-cell lymphomas. Blood, 2014,123(17):2636–2644
Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest, 2007,117(3):823–834
Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics, 2007,23(14):1846–1847
Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet, 2000,25(1):25–29
Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res, 2000,27(1):29–34.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 2009,4(1):44–57
Szklarczyk D, Franceschini A, Wyder S, et al.. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 2015,43:D447
Ono K, Muetze T, Kolishovski G, et al. CyREST: Turbocharging Cytoscape Access for External Tools via a RESTful API. F1000Res, 2015,4
Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 2003,4(1):2
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016,127(20):2375–2390
Wang C, Mckeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood, 2015,126(15):1741–1752
Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol, 2014,99(3):219–226
Paluch EK, Aspalter IM, Sixt M. Focal Adhesion-Independent Cell Migration. Annu Rev Cell Dev Biol, 2016,32(1):469
Zhu JJ, Luo J, Wang W, et al. Inhibition of FASN reduces the synthesis of medium-chain fatty acids in goat mammary gland. Animal, 2014,8(9):1469–1478
Wang Y, Zhang M, Xu H, et al. Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. Oncotarget, 2017,8(42):72182–72196
Morachis JM, Murawsky CM, Emerson BM. Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev, 2010,24(2):135–147
Islam S, Qi W, Morales C, et al. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas. Mol Cancer Ther, 2017,16(10):2083–2093
Jr LA, Schafernak KT, Geyer JT, et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 2016,128(8):1093–1100
Li Y, Shi X, Yang W, et al. Transcriptome profiling of lncRNA and co-expression networks in esophageal squamous cell carcinoma by RNA sequencing. Tumour Biol, 2016,37(10):1–10
Li S, Li H, Xu Y, et al. Identification of candidate biomarkers for epithelial ovarian cancer metastasis using microarray data. Oncol Lett, 2017,14(4):3967–3974
Ning X, Deng Y.. Identification of key pathways and genes influencing prognosis in bladder urothelial carcinoma. Onco Targets Ther, 2017,10:1673–1686
Ott GR, Cheng M, Learn KS, et al. Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). J Med Chem, 2016,59(16):7478–7496
Bosch R, Dieguez-Gonzalez R, Moreno MJ, et al. Focal adhesion protein expression in human diffuse large B-cell lymphoma. Histopathology, 2014,65(1):119–131
Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3,-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood, 2006,108(13):4178–4186
Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol, 2010,149(4):560–568
Hong JY, Hong ME, Choi MK, et al. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. Ann Oncol, 2014,25(1):182–188
Bai R, Ouyang TC, Morris S, et al. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 2000,96(13):4319
Chow C, Liu AY, Chan WS, et al. AKT plays a role in the survival of the tumor cells of extranodal NK/T-cell lymphoma, nasal type. Haematologica, 2005,90(2):274
Huang Y, De RA, De LL, et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 2010,115(6):1226
Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood, 2005,105(2):827–829
Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res, 2001,61(5):2194–2199
Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood, 2009,114(15):3265–3275
Hong JY, Hong ME, Choi MK, et al. The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma. Anticancer Res, 2015,35(4):2465–2474
Huang W, August A. The signaling symphony: T cell receptor tunes cytokine-mediated T cell differentiation. J Leukoc Biol, 2015,97(3):477–485
Martinez DB, Cuadros ME, Ruizdl PA, et al. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia, 2005,19(12):2254
Xiang L, Xie G, Ou J, et al. The Extra Domain A of Fibronectin Increases VEGF-C Expression in Colorectal Carcinoma Involving the PI3K/AKT Signaling Pathway. Plos One, 2012,7(4):e35378
Lossos IS, Czerwinski DK, Alizadeh AA, et al.. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med, 2004,350:1828–1837
Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 2008,111(12):5509
Vanesa G, Miguel GJ, Javier S, et al. Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. Plos One, 2009, 4(12):e8173
Zamani-Ahmadmahmudi M, Aghasharif S, Ilbeigi K. Prognostic efficacy of the human B-cell lymphoma prognostic genes in predicting disease-free survival (DFS) in the canine counterpart. BMC Vet Res, 2017,13(1):17
Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest, 2009,119(6):1429–1437
Brandt S, Montagna C, Georgis A, et al. The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma. Exp Hematol Oncol, 2013,2(1):27
Zhang H, Teng X, Liu Z, et al. Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis. J Exp Clin Cancer Res, 2015,34(1):16
Zenz R, Wagner EF. Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int J Biochem Cell Biol, 2006,38(7):1043–1049
Zhang J, Wu Z, Savin A, et al. The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G1. Sci Rep, 2018,8(1):16019
Ruco LP, Pomponi D, Pigott R, et al. Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin’s disease, and in non-Hodgkin’s lymphomas. An immunocytochemical study. Am J Pathol, 1990,137(5):1163–1171
Goto N, Tsurumi H, Takemura M, et al. Serum Soluble Tumor Necrosis Factor Receptor 1 Level is Associated with the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with the CHOP or R-CHOP Regimen. J Clin Exp Hematop, 2014,91(4):117–127
Nakamura N, Goto N, Tsurumi H, et al. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. Eur J Haematol, 2013,91(4):322–331
Honma Y, Sugita N, Kobayashi T, et al. TNF-α expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol, 2014,38(2):228–234
Dlouhy I, Filella X, Rovira J, et al.. High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leuk Res, 2017,59:20
Kato H, Nagasaka T, Ichikawa A, et al. Tumor necrosis factor-beta gene expression and its relationship to the clinical features and histopathogenesis of peripheral T-cell lymphomas. Leuk Lymphoma, 1994,16(1–2):125–133
Nocturne G, Boudaoud S, Ly B, et al.. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J Autoimmun, 2017,80:56–64
Ramezani S, Shirdel A, Rafatpanah H, et al. Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma. Med Microbiol Immunol, 2017,206(4):327–335
Boi M, Todaro M, Vurchio V, et al. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget, 2016,7(48):79637–79653
Guo X, Koff JL, Moffitt AB, et al. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene, 2017,36(29):4224–4232
Sebestyén A, Hajdu M, Kis L, et al. Smad4-independent, PP2A-dependent apoptotic effect of exogenous transforming growth factor beta 1 in lymphoma cells. Exp Cell Res, 2007,313(15):3167–3174
Macdonald I, Wang H, Grand R, et al. Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood, 1996,87(3):1147
Author information
Authors and Affiliations
Corresponding author
Additional information
The study was supported by grants from the National Natural Science Foundation of China (No. 81660036) and the Project of the Bingtuan Science and Technology (No. 2019DB012).
Conflict of Interest Statement
The authors declare that there is no conflict of interest with any financial organization or corporation or individual that can inappropriately influence this work.
Rights and permissions
About this article
Cite this article
Gao, Hx., Wang, Mb., Li, Sj. et al. Identification of Hub Genes and Key Pathways Associated with Peripheral T-cell Lymphoma. CURR MED SCI 40, 885–899 (2020). https://doi.org/10.1007/s11596-020-2250-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2250-9